Telix Pharmaceuticals Limited
TLX
$10.71
-$0.03-0.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.29% | 49.29% | 58.88% | 69.59% | 59.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.29% | 49.29% | 58.88% | 69.59% | 59.97% |
| Cost of Revenue | 108.39% | 108.39% | 96.49% | 155.73% | 61.38% |
| Gross Profit | 12.51% | 12.51% | 32.14% | 25.07% | 59.10% |
| SG&A Expenses | 33.63% | 33.63% | 45.95% | 60.00% | 61.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -563.04% | -563.04% | 106.70% | -92.54% | 161.24% |
| Total Operating Expenses | 61.66% | 61.66% | 69.01% | 96.76% | 57.10% |
| Operating Income | -69.28% | -69.28% | -47.42% | -70.00% | 93.85% |
| Income Before Tax | -102.86% | -102.86% | -141.45% | -114.40% | 31.20% |
| Income Tax Expenses | 364.45% | 364.45% | 27.95% | -125.57% | 130.03% |
| Earnings from Continuing Operations | -134.29% | -134.29% | -115.08% | -109.70% | -3.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.29% | -134.29% | -115.08% | -109.70% | -3.61% |
| EBIT | -69.28% | -69.28% | -47.42% | -70.00% | 93.85% |
| EBITDA | -48.35% | -48.35% | -25.67% | -53.36% | 94.97% |
| EPS Basic | -117.27% | -117.27% | -129.57% | -109.32% | 80.26% |
| Normalized Basic EPS | -126.77% | -126.77% | -134.67% | -108.02% | 407.61% |
| EPS Diluted | -121.45% | -121.45% | -130.63% | -109.55% | 74.32% |
| Normalized Diluted EPS | -128.47% | -128.47% | -136.11% | -108.20% | 387.78% |
| Average Basic Shares Outstanding | 97.48% | 97.48% | -48.77% | 4.12% | -46.57% |
| Average Diluted Shares Outstanding | 85.65% | 85.65% | -50.73% | 1.68% | -44.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |